MedTrace Logo

Drug Interaction Study - Assess Pharmacokinetics of Both AZD5672 and Atorvastatin

NCT00722956 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 12

Last updated 2010-12-02

No results posted yet for this study

Summary

The purpose of the study is to assess the pharmacokinetics of both AZD5672 (steady-state) and atorvastatin (single dose) when co administered in healthy volunteers

Conditions

  • Healthy Volunteers
  • Pharmacokinetics

Interventions

DRUG

AZD5672

100 mg once daily, 10 days

DRUG

atorvastatin

one single dose of 40 mg on day 10

Sponsors & Collaborators

Principal Investigators

  • Rod Hepburn · AstraZeneca R&D, Charnwood, UK

  • Maura Fallon · PAREXEL Clinical Pharmacology Research Unit

Study Design

Allocation
NON_RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2008-07-31
Primary Completion
2008-08-31
Completion
2008-08-31

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00722956 on ClinicalTrials.gov